[A18-26] Abiraterone acetate (prostate cancer) - Addendum to Commission A17-64
Last updated 07.06.2018
Project no.:
A18-26
Commission:
Commission awarded on 25.04.2018 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adults with newly diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC)
Result of dossier assessment:
Changes both in positive and in negative effects; as a conclusion still proof of a considerable added benefit
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A17-64 | Abiraterone acetate (prostate cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2018-06-07 A G-BA decision was published.